No deterioration in health-related quality of life in patients with axial spondyloarthritis followed for 5 years in ordinary outpatient clinics in the biological treatment era.
5 years
Axial spondyloarthritis
Biological treatment era
Health-related quality of life
Journal
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
accepted:
17
09
2019
pubmed:
29
9
2019
medline:
26
3
2020
entrez:
28
9
2019
Statut:
ppublish
Résumé
Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function and impaired health-related quality of life (HRQOL). The study aimed to explore the changes in HRQOL over 5 years in patients with ax-SpA and to identify baseline predictors associated with changes in HRQOL assessed using three HRQOL measures. Demographic, disease, medication and HRQOL data were collected at baseline and at 5-year follow-up. HRQOL was assessed using SF-6D, 15D and SF-36. Analyses involved McNemar, independent paired t tests and multiple regression. In the 240 (women 31%, men 69%) ax-SpA patients assessed (mean age 46 years), measures reflecting disease activity decreased and co-morbidities increased, and more patients were treated with biologic drugs during follow-up. No deterioration in HRQOL was observed between baseline and 5-year follow-up; indeed, there was a significant increase in SF-6D and SF-36 PCS scores. Improvement in HRQOL measured by SF-6D was associated with younger age, higher education, low Bath Ankylosing Spondylitis (BAS) Activity Index (BASDAI), high BAS Patient Global Score and high C-reactive protein; improvement in SF-36 PCS was associated with younger age, higher education, low BASDAI and no use of biological treatment at baseline. Our ax-SpA outpatient clinic patients, with more patients treated with biologic drugs during the 5-year follow-up, did not deteriorate in HRQOL. In fact, the physical dimension in HRQOL improved over the years, as did measures reflecting disease activity. Our study adds evidence to the importance of suppressing inflammation to maintain and improve HRQOL in ax-SpA patients.
Sections du résumé
BACKGROUND
BACKGROUND
Axial spondyloarthritis (ax-SpA) causes pain, fatigue, stiffness, loss of physical function and impaired health-related quality of life (HRQOL).
AIMS
OBJECTIVE
The study aimed to explore the changes in HRQOL over 5 years in patients with ax-SpA and to identify baseline predictors associated with changes in HRQOL assessed using three HRQOL measures.
METHODS
METHODS
Demographic, disease, medication and HRQOL data were collected at baseline and at 5-year follow-up. HRQOL was assessed using SF-6D, 15D and SF-36. Analyses involved McNemar, independent paired t tests and multiple regression.
RESULTS
RESULTS
In the 240 (women 31%, men 69%) ax-SpA patients assessed (mean age 46 years), measures reflecting disease activity decreased and co-morbidities increased, and more patients were treated with biologic drugs during follow-up. No deterioration in HRQOL was observed between baseline and 5-year follow-up; indeed, there was a significant increase in SF-6D and SF-36 PCS scores. Improvement in HRQOL measured by SF-6D was associated with younger age, higher education, low Bath Ankylosing Spondylitis (BAS) Activity Index (BASDAI), high BAS Patient Global Score and high C-reactive protein; improvement in SF-36 PCS was associated with younger age, higher education, low BASDAI and no use of biological treatment at baseline.
CONCLUSION
CONCLUSIONS
Our ax-SpA outpatient clinic patients, with more patients treated with biologic drugs during the 5-year follow-up, did not deteriorate in HRQOL. In fact, the physical dimension in HRQOL improved over the years, as did measures reflecting disease activity. Our study adds evidence to the importance of suppressing inflammation to maintain and improve HRQOL in ax-SpA patients.
Identifiants
pubmed: 31559519
doi: 10.1007/s11136-019-02308-4
pii: 10.1007/s11136-019-02308-4
pmc: PMC6962281
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-107Références
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Scand J Rheumatol. 2017 Nov;46(6):461-467
pubmed: 28293973
Clin Rheumatol. 2012 Apr;31(4):687-95
pubmed: 22203094
Ann Rheum Dis. 2014 Oct;73(10):1905-6
pubmed: 24989896
J Rheumatol. 2019 Sep;46(9):1075-1083
pubmed: 30770521
Ann Rheum Dis. 2018 Jan;77(1):3-17
pubmed: 28684559
Qual Life Res. 1999;8(1-2):45-54
pubmed: 10457737
Ann Med. 2001 Jul;33(5):328-36
pubmed: 11491191
Ann Rheum Dis. 2004 Dec;63(12):1605-10
pubmed: 15547084
Arthritis Care Res. 1999 Aug;12(4):247-55
pubmed: 10689989
RMD Open. 2017 Jan 27;3(1):e000396
pubmed: 28176964
Rheumatology (Oxford). 2016 Mar;55(3):419-28
pubmed: 26385369
J Clin Epidemiol. 1998 Nov;51(11):1077-86
pubmed: 9817125
J Rheumatol. 2011 Aug;38(8):1656-60
pubmed: 21632676
Qual Life Res. 2005 Aug;14(6):1523-32
pubmed: 16110932
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):857-72
pubmed: 25193010
Qual Life Res. 2016 Nov;25(11):2711-2723
pubmed: 27324038
Health Qual Life Outcomes. 2015 Jun 10;13:78
pubmed: 26149393
Curr Opin Rheumatol. 2000 Jul;12(4):239-47
pubmed: 10910174
J Eval Clin Pract. 2001 Nov;7(4):411-8
pubmed: 11737532
Arthritis Res Ther. 2018 Dec 27;20(1):284
pubmed: 30587228
Rheumatol Int. 2016 Mar;36(3):333-9
pubmed: 26643793
Arthritis Rheum. 1983 Nov;26(11):1346-53
pubmed: 6639693
Value Health. 2012 Dec;15(8):1100-7
pubmed: 23244813
Mod Rheumatol. 2013 Nov;23(6):1101-7
pubmed: 23224065
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Psychol Psychother. 2014 Sep;87(3):324-37
pubmed: 24123522
Qual Life Res. 2005 May;14(4):971-80
pubmed: 16041894
Physiotherapy. 2016 Jun;102(2):202-9
pubmed: 26119877
Clin Rheumatol. 2013 Jan;32(1):67-72
pubmed: 23015228
Qual Life Res. 2015 Mar;24(3):599-606
pubmed: 25145637
J Clin Epidemiol. 1998 Nov;51(11):1069-76
pubmed: 9817124
Rheumatol Int. 2015 Nov;35(11):1863-72
pubmed: 26254884
BMC Musculoskelet Disord. 2010 Sep 29;11:226
pubmed: 20920239
BMC Musculoskelet Disord. 2017 Aug 1;18(1):328
pubmed: 28764693
Arthritis Care Res (Hoboken). 2013 Sep;65(9):1482-9
pubmed: 23463610
Arthritis Rheum. 2008 Nov;58(11):3413-8
pubmed: 18975311
J Health Econ. 2002 Mar;21(2):271-92
pubmed: 11939242
Clin Rheumatol. 2018 Feb;37(2):429-438
pubmed: 29307092
Health Qual Life Outcomes. 2009 Mar 18;7:25
pubmed: 19296831
Rheumatology (Oxford). 2006 Oct;45(10):1288-93
pubmed: 16595514
Clin Rheumatol. 2018 Jun;37(6):1581-1588
pubmed: 29691772